Circassia says Duaklir now available in USA

21 October 2019

UK-based specialty pharma firm Circassia Pharmaceuticals (LSE: CIR) today announced the US launch of Duaklir (formoterol fumarate dihydrate/aclidinium bromide) for the maintenance treatment of chronic obstructive pulmonary disease (COPD) at the American College of Chest Physicians’ CHEST Annual Meeting 2019, which is currently ongoing in New Orleans, USA.

Notwithstanding the positive development, Circassia’s shares were down 1.9% at 16.85 pence in early afternoon trading.

Duaklir is a fixed-dose LAMA/LABA combination administered twice-daily via the breath-actuated, multi-dose inhaler Pressair. Circassia will promote Duaklir in the USA via its dedicated COPD sales force, alongside its established COPD treatment Tudorza (aclidinium bromide).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK